Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Mortality And Survival In Myasthenia Gravis: A Danish Population Based Study

P. Christensen, T. Jensen, I. Tsiropoulos, T. Sørensen, M. Kjær, E. Højer‐Pedersen, M. Rasmussen, E. Lehfeldt
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES To study mortality and survival of patients with myasthenia gravis. METHODS 290 patients with myasthenia gravis were studied, including 212 incident cases identified during a comprehensive epidemiological study of myasthenia gravis in western Denmark 1975-89. Follow up was performed on 31 December 1994. Survival curves were constructed using the life table method. Patient data were compared with data from the public Danish population statistics. Death certificates were provided from the National Registry of Death. RESULTS The annual average crude mortality rate was 1.8 per million (range 1.5-2.2). The myasthenia gravis related mortality rate (myasthenia gravis as underlying or contributory cause) was 1.4 per million (range 1.1-1.8). The age specific mortality rates were low below 50 years. After this age the mortality increased with age in both sexes; after 60 years more rapidly in men than in women. The overall survival rates three, five, 10, and 20 years from diagnosis were 85%, 81%, 69%, and 63% respectively. The survival of both sexes was shorter than that of the corresponding Danish population. Old age at diagnosis, a classification in Osserman-Genkins group IIB or III, and the presence of a thymoma were associated with a less favourable prognosis. The three, five, 10, and 20 year survival rates of thymectomised patients were 94%, 94%, 86%, and 79% respectively. The corresponding figures for the non-thymectomised patients were 78%, 71%, 56%, and 51%. A Cox regression analysis showed that this apparently significant effect of thymectomy was because the thymectomised patients were younger than the non-thymectomised patients. Furthermore, at the time of diagnosis of myasthenia gravis the non-thymectomised patients had a higher frequency of serious conditions associated with myasthenia gravis than the thymectomised patients. CONCLUSION Patients with myasthenia gravis generally have a relative good prognosis although their survival is shorter than that of the corresponding population. Old age, a classification in Osserman-Genkins group III, and the presence of a thymoma are associated with a less favourable prognosis. In this study, the apparently significant effect of thymectomy was because the thymectomised patients were younger than non-thymectomised patients and because the non-thymctomised patients had a higher frequency of serious conditions associated with myasthenia gravis.
This paper references
10.1111/j.1600-0404.1989.tb03793.x
Epidemiological study of myasthenia gravis in Sardinia, Italy (1958–1986)
M. Giagheddu (1989)
10.1212/WNL.40.5.786
The relationship of age to outcome in myasthenia gravis
D. Donaldson (1990)
10.1111/J.1600-0404.1968.TB07443.X
THE PREVALENCE OF SOME NEUROLOGICAL DISEASES IN ICELAND
K. Gudmundsson (1968)
Reports of public health and medical subjects, no 33 Appendix 1: errors of sampling of survivorship tables
M Greenwood (1926)
10.1177/003693306000501001
Myasthenia Gravis: A New Hypothesis
J. Simpson (1960)
10.1001/ARCHNEUR.1991.00530190081019
Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.
F. Somnier (1991)
10.1212/WNL.43.9.1779
Incidence and prevalence of myasthenia gravis in western Denmark
P. Christensen (1993)
for statistical advice
We Thank Dr N Kock-Henriksen
Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.
K. Osserman (1971)
Regression Models and Life-Tables
D.
10.1016/S0140-6736(75)92203-5
Myasthenia Gravis
D. Elmqvist (1966)
Incidence of myasthenia gravis in the Merseyside conurbation
Gw Pennington (1961)
10.1196/annals.1254.053
The Epidemiology of Myasthenia Gravis
L. H. Phillips (1994)
Incidence and prevalence of myasthenia gravis in western Denmark 1975 through 1989
Pb Christensen (1993)
10.1111/j.1749-6632.1987.tb51325.x
Long‐Term Corticosteroid Treatment of Myasthenia Gravis
T. R. Johns (1987)
Myasthenia gravis and myasthenic syndromes.
H. Oosterhuis (1992)
10.1038/bjc.1977.1
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
10.1212/WNL.42.10.1888
The epidemiology of myasthenia gravis in central and western Virginia
L. H. Phillips (1992)
10.1212/WNL.16.5.431
Myasthenia gravis
V. Perlo (1966)
Acta Neurol Scand
(1989)
10.1111/J.1600-0404.1984.TB00825.X
Epidemiology of myasthenia gravis in Norway
A. Storm-Mathisen (1984)
Epidemiology of myasthenia gravis.
Kurtzke Jf (1978)
10.1016/0022-510X(69)90090-2
Epidemiology of myasthenia gravis in Finland.
E. Hokkanen (1969)
Myasthenia gravis: evaluation of treatment in 1355 patients
Vp Perlo (1966)
10.1136/jnnp.52.10.1121
The natural course of myasthenia gravis: a long term follow up study.
H. Oosterhuis (1989)
10.1111/j.1749-6632.1987.tb51317.x
The Course of Myasthenia Gravis and Therapies Affecting Outcome a
D. Grob (1987)
Appendix 1: errors of sampling of survivorship tables
M Greenwood (1926)



This paper is referenced by
Farmakoterapie myasthenia gravis
MUDr.Stanislav Voháňka (2010)
How the application of human immunoglobulin in the treatment of myasthenia crisis changed the outcome of the disease.
E. Suljic (2010)
Manejo anestésico del paciente con miastenia gravis
Erika Reyes Espinosa del Río (2003)
10.1016/j.jneuroim.2015.10.018
Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese
C. Y. Lee (2015)
10.4103/0028-3886.55567
Thymectomy in myasthenia gravis.
J. Murthy (2009)
Molekulargenetische Analyse des B-Zell-Repertoires in Thymus und Blut von Myasthenia gravis Patienten
M. Witt (2007)
10.29819/ANT.200903.0004
Clinical features, diagnostic approach, and therapeutic outcome in myasthenia gravis patients with thymectomy.
A. Y. Notash (2009)
10.1136/jnnp.2007.118950
Neurological care and risk of hospital mortality for patients with myasthenia gravis in England
M. Hill (2007)
10.1034/j.1600-0404.2000.00014.x
Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment
L. Werneck (2000)
10.1111/j.1600-0404.2005.00374.x
Myasthenia gravis: clinical, immunological, and therapeutic advances
F. Romi (2005)
10.1007/S11940-002-0037-X
Thymectomy for myasthenia gravis
G. Gronseth (2002)
10.3390/medicina55070375
Comparative Outcomes of Respiratory Failure Associated with Common Neuromuscular Emergencies: Myasthenia Gravis versus Guillain–Barré Syndrome
A. Vellipuram (2019)
10.1016/S0035-3787(06)75109-8
Formes tardives de myasthénie. Étude comparative avec la myasthénie du sujet jeune
A. Barbaud (2006)
10.1016/B978-1-4377-0372-6.00018-9
18 – Treatment and Management of Disorders of the Neuromuscular Junction
S. Oh (2011)
Particularităţile vascularizaţiei bazinului în formarea hemoragiei retroperitoneale post-traumatice
G. Ghidirim (2011)
10.2147/IJGM.S129075
Factors predicting the outcomes of elderly hospitalized myasthenia gravis patients: a national database study
S. Tiamkao (2017)
10.1590/S0004-282X2008000200017
Haptoglobin study in myasthenia gravis.
Leonardo H Mendonça Oliveira (2008)
10.3988/jcn.2012.8.3.161
Incidence of Thymoma in Myasthenia Gravis: A Systematic Review
Zhifeng Mao (2012)
10.1016/j.jns.2007.03.019
Dysphonia as a primary manifestation in myasthenia gravis (MG): A retrospective review of 7 cases among 1520 MG patients
Wei-bin Liu (2007)
10.1007/978-1-59259-341-5_6
Thymoma-Associated Myasthenia Gravis
A. Marx (2003)
10.1007/s11596-014-1378-x
Effectiveness of thymectomy in non-thymomatous myasthenia gravis: a systematic review
Y. Luo (2014)
10.1186/1471-2377-10-46
A systematic review of population based epidemiological studies in Myasthenia Gravis
A. Carr (2010)
10.1212/WNL.0b013e3181a41211
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals
A. Alshekhlee (2009)
10.1186/s13023-017-0636-y
Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis
S. Weinreich (2017)
10.1016/j.nmd.2020.08.355
Mortality rates and causes of death in Swedish Myasthenia Gravis patients
E. Westerberg (2020)
10.1097/01.nrl.0000256352.77668.ef
Beneficial Effect of Tacrolimus on Myasthenia Gravis With Thymoma
T. Mitsui (2007)
10.1212/WNL.55.1.7
Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review)
G. Gronseth (2000)
10.1002/1097-4598(200012)23:12<1800::AID-MUS3>3.0.CO;2-X
Paraneoplastic syndromes of the spinal cord, nerve, and muscle
S. Rudnicki (2000)
10.1212/WNL.0000000000008747
Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome
A. Lipka (2020)
10.1186/1752-1947-4-61
Statin-associated weakness in myasthenia gravis: a case report
M. Keogh (2010)
10.1097/JTO.0b013e3181f1f62d
Epidemiology of Thymoma and Associated Malignancies
E. Engels (2010)
10.1007/s10072-012-1157-z
Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years
X. Huang (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar